Toyota to Accelerate Advancement of Fuel Cell Technology, Establishes Hydrogen Headquarters 
New EU trade rules could put poor countries in a billion dollar ‘green squeeze’ 
Electric air taxis are on the way – quiet eVTOLs may be flying passengers as early as 2025 
DoorDash Faces Challenges as Shares Tumble After Earnings Forecast 
Rishi Sunak wants to cut the cost of ‘sicknote’ Britain 
Adidas Unveils SS24 Paris Collection for Clay Court Season 
The yen plunges to 34-year low despite interest rate hike 
Walmart Is Shutting Its Health Centers, to Discontinue Virtual Healthcare Services 
Telegraph Newspaper Back on the Market After UAE-Backed Consortium Withdraws Takeover Bid 
Nigerians throw naira notes around to show love: but it could land you in jail 
Arby’s Unveils New Menu Additions Plus Beyoncé-Inspired Chardonnay-Infused Sauce 
Ferrari Unveils New 12Cilindri Models, Bolstering Its Petrol-Powered Lineup 
Impact investing in Paris suburban ‘banlieue’ neighbourhoods 
2025 Sees SK hynix's HBM Chips Fully Booked Amidst AI Surge 
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
